Nanoforming can open up exciting new opportunities — from increasing bioavailability to enabling sustained drug delivery. Discover the benefits that can be unlocked for both patients and the planet through the Nanoform toolbox, supported by data from relevant case studies.
Drugs have become more lipophilic and complex in structure, due to the industry’s move away from natural products. Despite this shift, fully synthetic drugs continue to grow in diversity and complexity. Innovative strategies are needed to improve bioavailability of these new drugs.
Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments in high demand. Discover new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs.
As pharma companies aim to overcome development obstacles, it is essential to implement GMP-compliance to ensure quality and safety. Explore how incorporating GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms holds promise for viable clinical and commercial success.
The healthcare sector is responsible for a significant portion of global greenhouse gas emissions. As the pharmaceutical industry innovates and evolves, placing sustainability at the forefront, learn how Nanoform can play a critical role in empowering your company's journey to net zero.
